The single-dose format ensures precision and reproducibility in administration, minimizing variability between doses and subjects and facilitating the generation of comparable clinical data compatible with controlled trial designs, including double-blind studies.
Oils and oral sprays present pharmacokinetic limitations associated with absorption control and interindividual variability, which may result in less predictable exposure profiles and undesired plasma peaks.
From the perspective of patient use and clinical practice, the absence of pulmonary exposure and the absorption through the buccal mucosa allow progress toward a more controlled administration, better tolerated and aligned with pharmaceutical and clinical objectives.
In regulated pharmaceutical programs, safety does not depend solely on the active ingredient, but also on the control of the pharmaceutical dosage form and its mode of administration.
Formats that allow controlled, reproducible dosing without pulmonary exposure facilitate a more robust safety evaluation, reduce sources of variability and favor institutional acceptance in clinical and hospital environments. This approach is particularly relevant when the objective is to integrate cannabinoids into medical programs under demanding regulatory and healthcare standards.
Medical Flowers Developments collaborates with pharmaceutical and biotech companies interested in cannabinoid clinical trials. The company maintains an open approach to professional discussions focused on development, innovation, and investment in regulated projects.
